Answers are grounded in this paper and cite their sources.
Demonstrates sensitive detection of microRNA in plasma, suggesting improved cancer diagnostics.
Objective: Develop a PCR-free DNA nanomachine (BDM) for selective picomolar detection of plasma miR-371a. Methods: A split 10–23 deoxyribozyme was engineered with substrate-delivering hooks and mismatch-introducing arms. The system was validated at 35°C using synthetic targets and patient plasma. Results and Discussion: BDM achieved a 1.6 pM limit of detection, showing a 9-fold sensitivity increase over hook-less controls. It maintained excellent specificity (LOD 1.3 pM) against a 25-fold excess of homologs and successfully identified clinical seminoma samples. Conclusions: BDM offers a sensitive, contamination-resistant alternative to RT-qPCR for non-invasive cancer liquid biopsies.
No takes yet. Share an insight, caveat, or question.
Alaji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: